Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears
G Lithwick-Yanai, N Dromi, A Shtabsky… - Journal of clinical …, 2017 - jcp.bmj.com
Aims The distinction between benign and malignant thyroid nodules has important
therapeutic implications. Our objective was to develop an assay that could classify …
therapeutic implications. Our objective was to develop an assay that could classify …
[HTML][HTML] Automatic ganglion cell detection for improving the efficiency and accuracy of hirschprung disease diagnosis
A Greenberg, A Aizic, A Zubkov, S Borsekofsky… - Scientific reports, 2021 - nature.com
Histopathologic diagnosis of Hirschsprung's disease (HSCR) is time consuming and
requires expertise. The use of artificial intelligence (AI) in digital pathology is actively …
requires expertise. The use of artificial intelligence (AI) in digital pathology is actively …
Electrolyte Imbalance in Anti-LGI1 Encephalitis: It Is Not All in Your Head
A Gadoth, M Nisnboym, Y Alcalay… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Antileucine-rich glioma-inactivated 1 (anti-LGI1) autoimmune
encephalitis was first described in 2010 and is today the most common type of limbic …
encephalitis was first described in 2010 and is today the most common type of limbic …
Profound decrease in glomerular arginine transport by CAT (cationic amino acid transporter)-1 contributes to the FLT-1 (FMS-like tyrosine kinase 1) induced …
M Shashar, A Zubkov, T Chernichovski… - …, 2019 - Am Heart Assoc
Endothelial dysfunction because of nitric oxide inactivation has been suggested to play a
role in the pathogenesis of preeclampsia. During pregnancy, L-arginine transport by CAT-1 …
role in the pathogenesis of preeclampsia. During pregnancy, L-arginine transport by CAT-1 …
[HTML][HTML] The risk of PD-L1 expression misclassification in triple-negative breast cancer
S Ben Dori, A Aizic, A Zubkov, S Tsuriel, E Sabo… - Breast Cancer Research …, 2022 - Springer
Purpose Stratification of patients with triple-negative breast cancer (TNBC) for anti-PD-L1
therapy is based on PD-L1 expression in tumor biopsies. This study sought to evaluate the …
therapy is based on PD-L1 expression in tumor biopsies. This study sought to evaluate the …
Apoptosis versus necrosis in tubal ectopic pregnancies following Methotrexate
Methotrexate administration for the treatment of tubal ectopic pregnancies has been shown
to cause tubal mass enlargement. Our hypothesis was that, by administrating Methotrexate …
to cause tubal mass enlargement. Our hypothesis was that, by administrating Methotrexate …
[HTML][HTML] Renal Tubular CD24 Upregulation Aggravates Folic Acid Induced Acute Kidney Injury: A Possible Role for T Regulatory Cells Inhibition in Mice
M Shashar, D Schwartz, A Zubkov, S Hoffman… - Journal of Personalized …, 2023 - mdpi.com
Acute kidney injury (AKI) is characterized by cell death and inflammation. CD24 is a protein
induced during tissue damage and is not expressed in mature renal tissue. We explored the …
induced during tissue damage and is not expressed in mature renal tissue. We explored the …
Thromboelastography versus bleeding time for risk of bleeding post native kidney biopsy
A Gal-Oz, A Papushado, I Kirgner, S Meirsdorf… - Renal …, 2020 - Taylor & Francis
Introduction The risk of bleeding has led to screening of the primary hemostasis before renal
biopsy. A bleeding time test (BT) is considered standard practice, but reliance on this test is …
biopsy. A bleeding time test (BT) is considered standard practice, but reliance on this test is …
Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast …
M Taya, K Merenbakh-Lamin, A Zubkov, Z Honig… - 2024 - researchsquare.com
Purpose All patients with metastatic breast cancer (MBC) expressing estrogen receptor-α
(ESR1) will eventually develop resistance to endocrine therapies. In up to 40% of patients …
(ESR1) will eventually develop resistance to endocrine therapies. In up to 40% of patients …
Abstract B085: Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway …
M Taya, K Merenbakh-Lamin, A Zubkov, Z Honig… - Molecular Cancer …, 2023 - AACR
Purpose: All patients with metastatic breast cancer (BC) expressing estrogen receptor α
(ESR1) will eventually develop resistance to endocrine therapies. In up to 40% of cases, this …
(ESR1) will eventually develop resistance to endocrine therapies. In up to 40% of cases, this …